Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00004871
First received: March 7, 2000
Last updated: March 9, 2010
Last verified: March 2010

March 7, 2000
March 9, 2010
May 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004871 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate (PB, NSC 657802) in Combination With 5-Azacytidine (5-AZA, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells.

PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.

OBJECTIVES:

  • Determine the safety and toxicity of azacitidine in combination with phenylbutyrate in patients with recurrent, refractory, or untreated acute myeloid leukemia or myelodysplastic syndrome.
  • Determine the minimal effective pharmacologic dose of azacitidine required to consistently inhibit DNA methyltransferase in this patient population.
  • Obtain preliminary clinical and/or laboratory data suggesting potential therapeutic activity of this combination regimen in these patients.

OUTLINE: This is a dose deescalation study of azacitidine.

Patients receive azacitidine subcutaneously daily on days 1-5 and 29-33 followed by phenylbutyrate IV continuously on days 5-12 and 33-40. Treatment continues for at least 2 courses in the absence of disease progression. Patients with responsive disease may receive an additional 2 months of therapy.

Cohorts of 3-6 patients receive deescalating doses of azacitidine until the minimal effective pharmacologic dose (MEPD) is determined. The MEPD is defined as the dose above the dose at which more than 1 of 6 patients do not meet the target enzyme inhibition of greater than 90%.

Once the MEPD and toxicity have been established for a 5 day schedule, daily dose schedule of azacitidine is increased to 10, 14, and 21 days, followed by phenylbutyrate for 7 days. Courses are repeated every 28 days.

PROJECTED ACCRUAL: Approximately 32 patients will be accrued for this study within 2 years.

Interventional
Phase 1
Primary Purpose: Treatment
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Diseases
  • Drug: azacitidine
  • Drug: sodium phenylbutyrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed myelodysplastic syndrome (MDS) indicating one of the following:

    • Refractory anemia (RA)
    • Primary refractory leukopenia or thrombocytopenia with MDS morphology
    • RA with excess blasts (RAEB)
    • RA with ringed sideroblasts (RARS)
    • Chronic myelomonocytic leukemia
    • RAEB in transformation
  • RA or RARS must have at least one of the following:

    • Absolute neutrophil count less than 1,000/mm^3
    • Untransfused hemoglobin less than 8 g/dL
    • Platelet count less than 20,000/mm^3
    • Anemia
    • Thrombocytopenia requiring transfusion
    • High risk chromosomal abnormalities
  • Any stage of MDS allowed including:

    • Previously untreated MDS
    • Refractory MDS allowed if failure to achieve remission following prior intensive chemotherapy of at least 1 month ago
  • Relapsed, refractory, or untreated acute myeloid leukemia (AML) with the following:

    • WBC less than 30,000/mm^3
    • Stable for at least 2 weeks
    • Unlikely to require cytotoxic therapy during study
  • Untreated AML with poor risk factors for response to standard therapy including:

    • Greater than 60 years old
    • AML occurs in setting of antecedent hematologic disorder
    • High risk chromosomes (e.g., abnormalities of chromosome 5 or 7 or complex cytogenetic abnormalities)
    • Medical conditions that preclude cytotoxic chemotherapy as primary therapy
  • Refusal of cytotoxic chemotherapy allowed
  • No clinical evidence of CNS leukostasis or CNS leukemia

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Zubrod 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics
  • Hemoglobin at least 8 g/dL (transfusion allowed)

Hepatic:

  • Bilirubin less than 2.0 mg/dL (unless due to hemolysis or Gilbert's disease)

Renal:

  • Creatinine less than 2.0 mg/dL

Cardiovascular:

  • No disseminated intravascular coagulation

Pulmonary:

  • No pulmonary leukostasis

Other:

  • No active infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception 2 weeks prior, during and 3 months after study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 3 weeks since prior biologic therapy including colony stimulating factors and recovered

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • At least 3 weeks since prior hormonal therapy and recovered

Radiotherapy:

  • At least 3 weeks since prior radiotherapy and recovered

Surgery:

  • Not specified
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00004871
CDR0000067531, J9950, U01CA070095, R01CA067803, P30CA006973, JHOC-99072307, NCI-T99-0092, JHOC-J9950
Not Provided
Not Provided
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Steven D. Gore, MD Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP